CIC has 6 sites across Canada and engagements with 5 international sites.
CIC completes 2-3 studies per year: avg. 50% crossover studies and 50% parallel studies.
CIC’s accomplishments: from identifying new therapies to publishing novel data.
BRONCHOPROVOCATION Inhaled allergen (PC20/PD20, early & late asthmatic responses) Methacholine airway hyperresponsiveness Inhaled mannitol (Aridol®) Exercise-induced bronchoconstriction Hypertonic saline Capsaicin cough challenge […]